Urinary pterins in atypical phenyl-ketonuria: 60

Niederwieser, A.; Bieri, Jost H.; Blehovà, B; Curtius, Hans−Christoph; Matasović, A.; Rey, Francisco Escobar del; Schircks, Bernhard; Viscontini, M.; Prader, A.

doi:10.1203/00006450-198002000-00087

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measurement of urinary pteridines is of clinical value in the recognition of variants in phenylketonuria patients (71,42,64 deficiency (75,64) were demonstrated. These data were confirmed by Dhondt and coworkers (67) using age-paired comparisons.…”

Section: Excretion Of Pteridines In Patients With Benign Diseasesmentioning

confidence: 99%

Pteridines in the Assessment of Neoplasia

Hausen¹,

Wachter²

1982

CCLM

View full text Add to dashboard Cite

Summary: Biological processes which inight explain the association of pteridine excretion with proliferation are still unknown. Difficulties in the analysis and the determination of naturally occurring pteridines are described. The best quantitative estimations were achieved when measurement of non-reduced forms was attempted. The performance characteristics of such a method for neppterin by high performance liquid chromatography on reversed phase are given. Enhanced proliferation and dedifferentiation in cell cultures and organisms is paralleled by excretion of unconjugated pteridines into the medium or urine. Urinary neopterin in healthy subjects and in patients with benign diseases was only significantly raised in patients with viral diseases. Howevei, an elevation of urmary neopterin occurred in a wide variety of malignant diseases. In haematologic neoplasias correlatipns of neopterin values to clinicäl features, to tumour staging, and to laboratory data were apparent. The clinicäl Utility of neopterin measurement was also demonstrated in patients with gynaecologic tumours, particularly in patients with ovarian carcinoma. In both homogenepus patient groups the neopterin assay may provide an additional aid for prognosis and for monitoring therapy. Comparison of the neopterin assay with already established tumour marker substances at least revealed no inferiority in sensitivity. The present results justify extensive investigations in prder to eväluate further the clinicäl applicäbility of the neopterin assay. Pteridine in der Diagnostik von Neoplasien

show abstract

Section: Excretion Of Pteridines In Patients With Benign Diseasesmentioning

confidence: 99%

Pteridines in the Assessment of Neoplasia

Hausen¹,

Wachter²

1982

CCLM

View full text Add to dashboard Cite

show abstract

“…This would explain the excessive urinary excretion of neopterin and dihydroneopterin [10][11][12] and 3'-hydroxysepiapterin [4] as well as the response of these patients to L-erythro-tetrahydrobiopterin, L-erythro-dihydrobiopterin and even better to L-sepiapterin [ 11 ] by normalization of tile elevated serum phenylalanine concentration.…”

Section: Dihydrobiopterinmentioning

confidence: 99%